EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting

Yanying Li, Yuming Wan, Xiaoyun Yang, Ping Chen, Yan Gui, Lang He, Yingwei Xie, Jing Tian, Ping Duan, Guangguo Liu, Yu Sun, Jiang Zhu

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05766-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Yanying Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37…. Hauptthemen laut MEDLINE: Cisplatin, Vomiting, Nausea, Morpholines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Neurokinin 1 receptor antagonists included prophylactic treatment was recommended for patients who receive one-day cisplatin chemotherapy. It is unclear whether the prolonged administration of fosaprepitant is effective for three-day cisplatin-based chemotherapy induced nausea and vomiting (CINV). We aim to explore the prophylactic antiemetic efficacy and safety of two doses of fosaprepitant included regimen in the patients receiving multiple-day cisplatin chemotherapy.

Methods

This randomized, parallel-group, open-labelled study was conducted in nine hospitals between February 2021 and February 2023. Patients diagnosed as lung cancer and chemotherapy naive were screened. Eligible participants were scheduled to be treated with highly emetogenic chemotherapy regimen which including three days of cisplatin. Then they were randomly divided into the experimental group (two doses of fosaprepitant, Group 2DF) and the control group (one dose of fosaprepitant, Group C). The primary endpoints included the safety and the average none CINV days (NCDs). This study was registered on the website of chictr.org.cn, number ChiCTR2100042665.

Results

Overall, 204 participants were randomly assigned, and 198 patients were analyzed. No statistical difference in adverse events was found between the two groups. All treatment-related adverse effects for fosaprepitant observed were of grade 1–2. The average NCDs of Group 2DF was significantly more than Group C (18.21 ± 3.40 days vs 16.14 ± 5.20 days, P = 0.001). Furthermore, the better life function score was achieved in Group 2DF according to FLIE questionnaire.

Conclusion

The administration of two-dose fosaprepitant was safe and more effective than one dose in protecting patients from CINV induced by three-day cisplatin included chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinVomitingNauseaMorpholinesAntiemeticsHumansMaleFemaleMiddle AgedLung NeoplasmsAgedAdultAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents

Stichwörter der Autor:innen

CINVFosaprepitantThree-day cisplatinTwo doses

Substanzen

fosaprepitantCisplatinMorpholinesAntiemeticsAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, 610041, China.
  • Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Medical Oncology, Shangjin Nanfu Hospital, West China Hospital, Chengdu, China.
  • Panzhihua University Affiliated Hospital, Panzhihua, China.
  • Lung Cancer Ward of Chengdu 7th People's Hospital, Chengdu, China.
  • Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.

Zitieren

APA

Li, Y., Wan, Y., Yang, X., Chen, P., Gui, Y., He, L., Xie, Y., Tian, J., Duan, P., Liu, G., Sun, Y., & Zhu, J. (2024). Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05766-7

Vancouver

Li Y, Wan Y, Yang X, Chen P, Gui Y, He L, et al. Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05766-7

BibTeX
@article{Li2024,
  author = {Li, Yanying and Wan, Yuming and Yang, Xiaoyun and Chen, Ping and Gui, Yan and He, Lang and Xie, Yingwei and Tian, Jing and Duan, Ping and Liu, Guangguo and Sun, Yu and Zhu, Jiang},
  title = {Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05766-7}
}
Kostenlos starten →